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INTRODUCTION
Both diabetes mellitus and primary hypothyroidism are
major endocrine disorders leading to secondary hyperlipopro-
teinemia. In many cases of primary hypothyroidism, the levels
of both total cholesterol and low density lipoprotein (LDL)
are increased and some cases have a high concentration of
triglycerides (1-3). About half of the type 2 diabetes patients
were associated with type IV hyperlipoproteinemia, in which
the very low density lipoprotein (VLDL) level was usually
elevated (4). These type 2 diabetes patients also frequently
have type V hyperlipoproteinemia. To date, there have been
only a few case reports of type 2 diabetes patients with both
type V hyperlipoproteinemia and eruptive xanthomas (5-8),
but there has been no report of patients with diabetes melli-
tus and hypothyroidism associated with eruptive xanthomas.
We report here on a case of a 48-yr old female patient who
was diagnosed with type 2 diabetes and primary hypothy-
roidism associated with both type V hyperlipoproteinemia
and eruptive xanthomas.
CASE REPORT
A 48-yr old female patient was admitted to our hospital
because of generalized weakness and right flank pain for sev-
eral months. She was diagnosed with hypercholesterolemia
by biochemical tests, and had rouleaux formations on the
peripheral blood smear analysis that was done at a local pri-
vate clinic (Fig. 1). In order to continue her further evalua-
tion and management, she was transferred to the department
of internal medicine of Gyeongsang National University Hos-
pital. She did not complain of any other abdominal pain or
tingling sensation on her extremities. According to her past
medical history, she was diagnosed as autoimmune thyroidi-
tis and primary hypothyroidism in 1992 and began to take
levothyroxine 100  g daily. However, she took the medicine
irregularly and then was lost to follow-up. In 1998, she revis-
ited the of endocrinology and metabolism outpatient depart-
ment with complaints of generalized weakness and fatigue.
She still had hypothyroidism as well as uncontrolled diabetes
mellitus and dyslipidemia. Thereafter, she took levothyroxine
100-150  g daily in combination with a low fat diet and reg-
ular exercise therapy. After one month, her thyroid function
test revealed the following results; TSH 61.13 mU/L, total
T4 61 nM/L, total T3 1.4 nM/L, total cholesterol 8.0 mM/L,
triglyceride 9.6 mM/L, HDL cholesterol 0.83 mM/L, and
HbA1c 6.6%. After this, she started taking simvastatin and
gemfibrozil, but not oral hypoglycemic agents because at this
time the fasting blood glucose level was 8.7 mM/L. There-
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A Case of Hypothyroidism and Type 2 Diabetes Associated with
Type V Hyperlipoproteinemia and Eruptive Xanthomas 
Primary hypothyroidism and type 2 diabetes are both typically associated with the
increased level of triglycerides. To date, there have been only a few case reports
of type 2 diabetes patients with both type V hyperlipoproteinemia and eruptive xan-
thomas, but there have been no reports of hypothyroidism patients associated with
eruptive xanthomas. We report here on a case of a 48-yr old female patient who
was diagnosed with type 2 diabetes and primary hypothyroidism associated with
both type V hyperlipoproteinemia and eruptive xanthomas. We found rouleaux for-
mation of RBCs in peripheral blood smear, elevated TSH, and low free T4 level, and
dyslipidemia (total cholesterol 18.1 mM/L, triglyceride 61.64 mM/L, HDL 3.0 mM/L,
and LDL 2.54 mM/L). She has taken fenofibrate, levothyroxine, and oral hypoglycemic
agent for 4 months. After treatment, both TSH level and lipid concentration returned
to normal range, and her yellowish skin nodules have also disappeared.
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after, she did not keep scheduled visit. We could not find any
skin symptoms or signs from her medical record. She denied
smoking or alcohol intake and took no drugs except levothy-
roxine irregularly. One sister among the 5 siblings in her
family was diagnosed with dyslipidemia (her lipid profiles
performed on December 2002 were total cholesterol 8.30
mM/L, LDL cholesterol 4.32 mM/L, HDL cholesterol 1.37
mM/L and, triglyceride 3.7 mM/L). In addition, one of the
patients brother has type 2 diabetes mellitus, but he did not
have the dyslipidemia. 
On the physical examination, her waist circumference and
hip circumference was 33 inch and 37 inch (W/H ratio, 0.87)
respectively, and the body mass index (BMI) was 26.2 kg/m2.
Diffuse goiter with firm consistency was palpated on her
anterior neck. Her breathing was clear, and hepatosplenome-
galy or tenderness was not found upon abdomen palpation.
Several yellowish skin nodules were observed on both her
elbows and thighs (Fig. 2A).
On admission, her laboratory findings were as follows;
hemoglobin 12.2 g/dL, RBC volume 32%, WBC 5,100/ L,
platelet 210,000/ L, postprandial 2 hr blood glucose 14
mM/L, total protein 99 g/L, albumin 44 g/L, total bilirubin
13.6  M/L, ALP 61 IU/L, AST 24 IU/L, ALT 28 IU/L, BUN
3.7  M/L and, creatinine 97.5  M/L. Her serum electrolytes
were sodium 124.1 mM/L, potassium 3.5 mM/L, chloride
90 mM/L, calcium 2.5 mM/L, and phosphorus 0.9 mM/L.
The urinalysis was normal. Lipid profiles were as follows;
total cholesterol 18.1 mM/L, triglyceride 61.64 mM/L, HDL
3.0 mM/L, and LDL 2.54 mM/L. Amylase and lipase levels
were normal. The thyroid function tests, determined by a
radioimmunoassay method (Immunotech, A Beckman coulter
company, France), revealed that she has chronic autoimmune
thyroiditis and primary hypothyroidism; TSH 72.69 mU/L
(normal range; 0.17-4.05 mU/L), free T4 0.22 ng/dL (nor-
mal range; 0.95-2.23 ng/dL), free T3 0.46 pg/mL (normal
range; 1.60-3.80 pg/mL). Glycosylated hemoglobin A1c was
9.4%. The excreted protein amount in 24 hr collected urine
was 413.7 mg/day. On the second day after admission, a creamy
and clouded layer was found in her fasting whole blood that
had been placed in the refrigerator for 30 min. The concentra-
tion of lipoprotein (a) measured by a rate rephelometry method
(Beckman, CA, U.S.A.) was 9 mg/dL. Lipoprotein electro-
phoresis findings indicated that the patient had type V hyper-
lipoproteinemia (Fig. 3). Apolipoproteins determined by a
single radial immunodiffusion method (Hitachi 7050 chem-
istry analyser, Japan) were as follows; apolipoprotein C-II 42.0
mg/dL (normal range: 1.5-3.8 mg/dL), apolipoprotein C-III
100 mg/dL (normal range: 5.4-9.0 mg/dL), and apolipopro-
tein E 27.0 mg/dL (normal range: 2.8-4.6 mg/dL).
We carried out urinalysis and abdominal computed tomog-
raphy to evaluate her right flank pain and tenderness. Alth-
ough fatty liver was observed on the abdominal computed
tomography, there was no abnormality noted that could be
causing pain. Consultation with the rehabilitation department
concluded that the patient had fibromyalgia.
The patient was diagnosed as hypothyroidism and type 2
Fig. 1. Rouleaux formation of red blood cells. Peripheral blood
smear shows the rouleaux formation of RBCs, a stack of coins
(×1,000).
Fig. 2. Eruptive xanthoma. (A) Eruptive xanthoma appeared over the elbow of the patient before medication. (B) The lesion of eruptive
xanthomas was completely regressed after medications.504 J.R. Park, T.S. Jung, J.H. Jung, et al.
diabetes that presented as hyperlipidemia, and she began to
take glimepiride, voglibose, levothyroxine (100  g daily),
and fenofibrate (200 mg). Also, she began to visit the reha-
bilitation department to help releave her pain. She was then
discharged when the blood glucose level and pain have been
controlled. She has visited the outpatient department for reg-
ular check-ups. She has taken fenofibrate for two months.
Currently, the level of both TSH and lipid concentration in
blood have returned to the normal values (Table 1). Also, the
patient’s yellowish skin nodules have disappeared (Fig. 2B).
DISCUSSION
There are 2 types of hyperlipidemia; one is a primary form
caused by genetic abnormalities, the other is the secondary
hyperlipidemia resulting from other diseases or medications
such as diabetes mellitus, hypothyroidism, nephrotic syn-
drome, estrogen treatment, and alcohol abuse (9).
Hypothyroidism is classically manifested with an elevation
of the plasma LDL cholesterol, and it can also be associated
with high plasma triglycerides (1, 2). The HDL cholesterol
level is usually unchanged or slightly decreased (10, 11). The
elevated plasma LDL cholesterol in hypothyroidism is typi-
cally associated with impaired clearance of LDL due to the
decreased LDL receptor expression (12, 13). And the elevat-
ed triglycerides are induced by decrease of lipoprotein lipase
activity (1).
Also, it is well known that dyslipidemia often developed
in patients with poorly controlled diabetes mellitus. Type
IV dyslipidemia, i.e. an increase of VLDL cholesterol, is the
most common form seen in type 2 diabetes, and type IIb,
type V, and type IIa dyslipidemia follow.
Xanthomas are the localized deposit of lipids in the skin
and these occur rarely in the subcutaneous layer. It is classi-
fied as eruptive, tendinous, tuberous, and planar, by deposit-
ed anatomic distribution and mode of development (14). The
eruptive xanthomas are typically found in patients with severe
hypertriglyceridemia, increased chylomicron, and increased
VLDL cholesterol. The lesions most commonly develop in
type V hyperlipidemia, and they appear on pressure sites such
as the extensor surface of the lower and upper extremities and
the buttocks (15). Treatment of secondary eruptive xanthomas
requires correction of the underlying diseases or removal of
the causative agents, and there have been few cases of com-
plete regression reported.
This patient was diagnosed with hypothyroidism and dia-
betes mellitus in 1998, but at the time plasma glucose and
glycosylated hemoglobin A1c level of the patient were not
elevated. Hypothyroidism in the patient might have result-
ed in type V hyperlipoproteinemia because of the increased
level of LDL. In addition, this patient showed an elevated
level of apolipoproteins in the serum. Typically, apolipopro-
tein C-II deficiency is associated with type V hyperlipopro-
teinemia. But, we cannot rule out genetic factors leading to
her lipoprotein abnormalities because one of her sisters has
hyperlipidemia. From these results, we have assumed that
hypothyroidism and insulin resistance in this patient induced
hyperlipidemia together with her genetic factors (16). Famil-
ial hypertriglyceridemia may be exacerbated by hypothy-
roidism, estrogen therapy, uncontrolled diabetes mellitus
and alcohol. Therefore, determination of the lipid profiles
among her family members will clear up the diagnosis. The
Fig. 3. A profile of lipoproteins. A result of lipoprotein electrophore-
sis indicates that the patient has type V hyperlipoproteinemia. There
are well defined bands of chylomicrons and grossly elevated pre-
lipoproteins. HDL ( -lipoprotein) and VLDL (pre- lipoprotein) move
with  1-globulins (the most left area) and  2-globulins (first peaks).
LDL ( -lipoprotein) migrates with beta-globulins and chylomicron
(second peak) remains at the origin.
Fraction % % Range
Alpha 2.0 lo 20.4 46.4
Pre-Beta 49.3 hi 3.8 33.8
Beta 17.2 lo 36.5 59.1
Cholesterol 940
Triglyceride 2900
TSH (mU/L) Free thyroxine
(T4) (ng/dL)
HbA1c (%) FBS/PP2
(mM/L)
Total cholesterd
(mM/L)
LDL
(mM/L)
Triglyceride
(mM/L)
November 1998 61.13 4.76 (total T4) 6.6 8.0/10.8 8.02 9.63
January 1999 53.66 1.22 6.6 nd/8.7 8.38 11.30
June 2003
(Fig. 2A) 72.69 0.22 9.4 7.8/14 18.1 2.54 61.64
August 2003 20.51 1.06 7.1 10.6/17.3 5.87 2.29
November 2003
(Fig. 2B) 0.21 1.50 8.0 8.9/14 6.23 2.25
Table 1. Laboratory data of the patient with type V hyperlipoproteinemia in hypothyroidism and diabetes mellitus
nd, not done; HDL, high density cholesterol; LDL, low density cholesterol.Hypothyroidism Associated with Eruptive Xanthomas  505
recovery of her normal lipid profile and the coincidental dis-
appearance of eruptive xanthomas after treatment with fenofi-
brate, levothyroxine, and oral hypoglycemic agents for two
months also suggests that her derangement of lipid metabolism
and skin signs are secondary results of the hypothyroidism
and diabetes. 
This patient also showed the rouleaux formation in her
peripheral blood smear. The rouleaux formation, RBCs aggre-
gation, commonly occurs with hypergammaglobulinemia
such as multiple myeloma. Hypertriglyceridemia also increas-
es the rouleaux formation rate (17). In many cases, lipemic
retinalis and recurrent pancreatitis attacks were associated
with hypertriglyceridemia (18), but these conditions did not
develop in this case.
In conclusion, our patient who was initially diagnosed with
type 2 diabetes and primary hypothyroidism had type V
hyperlipoproteinemia as well as eruptive xanthomas. This
case report might play an important role for not only show-
ing how to correctly diagnose patients with type 2 diabetes
and hypothyroidism that manifest with eruptive xanthomas
and rouleaux formation in peripheral blood smear, but also
serves as a clinical example for how to effectively treat them. 
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